Abstract
Objective: The objective of the present study was to formulate flurbiprofen (FLB) emulgel, evaluation of the formulations and the selection of an optimized formulation through in vitro drug release and drug content studies. Flurbiprofen is a non-steroidal anti-inflammatory drug (NSAID) requiring frequent administration and its chronic intake can lead to systemic side effects like gastric irritation and GI bleeding. The development of a dermal drug delivery system can overcome these side effects.
 Methods: The emulgel formulations were produced using different combinations of oil and emulsifying agents. Carbopol 940 was used as a gelling agent. The prepared emulgels were evaluated for general appearance, pH, spreadability, extrudability, drug content, in vitro drug release, average globule size and viscosity.
 Results: Optimized formulation F7 showed a better in vitro drug release compared to the marketed gel preparation. The stability study for the optimized formulation was carried out at 25 °C/60 % RH for 3 mo and the emulgel was found to be stable concerning the physical appearance, pH and drug content.
 Conclusion: The study revolved around the formulation of emulgel containing Flurbiprofen for dermal delivery of the drug. Emulgel was formulated with the purpose to enhance the permeation of poorly water-soluble drug FLB. The study concluded that the optimized emulgel containing FLB exhibited better in vitro drug release profile compared to the marketed formulation.
Highlights
Non-Steroidal Anti-inflammatory Drugs (NSAIDs) are the category of drugs used for the long term treatment of Rheumatoid arthritis (RA) and osteoarthritis
Flurbiprofen, [2-(2-fluoro-4-biphenylyl) propionic acid] is a potent chiral non-steroidal anti-inflammatory agent with antipyretic and analgesic action and is approved by USFDA for the treatment of rheumatoid arthritis, osteoarthritis, and alkylosing spondylitis. It has a half-life of 4.7 h and needs frequent administration and its chronic intake could result in systemic side effects like gastric irritation and gastric bleeding [1,2,3,4,5]
Flurbiprofen was obtained as a gift sample from FDC-Ltd (Roha Maharashtra), carbopol 940 was obtained from lubrizol, tween 80, span 80 and triethanolamine were obtained from molychem, liquid paraffin was obtained from SD-chemicals and fines ltd
Summary
Non-Steroidal Anti-inflammatory Drugs (NSAIDs) are the category of drugs used for the long term treatment of Rheumatoid arthritis (RA) and osteoarthritis. Flurbiprofen, [2-(2-fluoro-4-biphenylyl) propionic acid] is a potent chiral non-steroidal anti-inflammatory agent with antipyretic and analgesic action and is approved by USFDA for the treatment of rheumatoid arthritis, osteoarthritis, and alkylosing spondylitis. It has a half-life of 4.7 h and needs frequent administration and its chronic intake could result in systemic side effects like gastric irritation and gastric bleeding [1,2,3,4,5]. Emulgels are either oil in water or water in oil emulsions gelled by mixing with a gelling agent and combine the properties of both gel and emulsions thereby acting as a dual control release systems [6,7]
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Pharmacy and Pharmaceutical Sciences
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
